JPMorgan initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $23 price target The firm says its bullish thesis is based on Camp4’s ASO RNA Actuator Platform, which it believes offers the potential to systematically restore the expression of specific proteins as a means of modifying disorders due to genetic haploinsufficiency. It sees the shares becoming constructive with potentially de-risking clinical readouts in Q1 and the second half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAMP:
- Camp4 Therapeutics initiated with an Overweight at Piper Sandler
- Opening Day: Polyrizon, Gelteq debut in quiet IPO week
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
